Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribonucleotide reductase small subunit M2 (RRM2) is an essential enzyme for DNA synthesis and repair. It catalyzes the conversion of ribonucleotides to deoxyribonucleotides. Its expression is cell cycle-dependent, and dysregulation is linked to cancer proliferation. RRM2 is considered a therapeutic target and a potential biomarker for cancer prognosis.
Catalyzes the conversion of ribonucleotides to deoxyribonucleotides, providing precursors required for DNA synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribonucleotide reductase small subunit M2 (RRM2).